skip to main content

RA Independent ILD Risk — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateRheumatoid ArthritisRA Independent ILD RiskSCE Rheumatology

A 55-year-old woman with rheumatoid arthritis who has never received methotrexate or leflunomide asks whether rheumatoid arthritis itself increases her risk of interstitial lung disease. Which statement best reflects current evidence?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: ERA itself increases ILD risk; older age, male sex, smoking, seropositivity and active inflammation further increase risk.

RA-associated ILD is an extra-articular manifestation of RA and is not explained solely by antirheumatic drug exposure. Established clinical risk factors include older age, male sex, smoking, RF or anti-CCP positivity—particularly higher titres—and greater inflammatory disease activity. The MUC5B promoter variant is additionally associated with RA-ILD, especially the UIP pattern. Prevalence varies substantially with case ascertainment: contemporary analyses suggest approximately 10–13% in lower-bias or multimodally assessed populations, while systematic HRCT detects more subclinical disease. Methotrexate can cause a distinct, potentially acute hypersensitivity-type pneumonitis, but observational evidence does not show that it causes chronic fibrotic RA-ILD. Therefore B is incorrect; smoking increases but does not fully account for risk, excluding D. A and E incorrectly deny the persistent, independent association between RA and parenchymal ILD.

Reference: Antoniou KM et al. ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease, RA screening algorithm, 2026. https://pubmed.ncbi.nlm.nih.gov/42078587/